Literature DB >> 16849341

Significance of anti-inflammatory effects of PPARgamma agonists?

G Rogler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16849341      PMCID： PMC1856254          DOI： 10.1136/gut.2005.089946

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  54 in total

Review 1.  The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

Authors:  M Ricote; J T Huang; J S Welch; C K Glass
Journal:  J Leukoc Biol       Date:  1999-11       Impact factor: 4.962

Review 2.  Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions.

Authors:  L Michalik; W Wahli
Journal:  Curr Opin Biotechnol       Date:  1999-12       Impact factor: 9.740

Review 3.  Roles of PPARs in health and disease.

Authors:  S Kersten; B Desvergne; W Wahli
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

Review 4.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions.

Authors:  P Escher; W Wahli
Journal:  Mutat Res       Date:  2000-03-17       Impact factor: 2.433

Review 5.  Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.

Authors:  G Chinetti; J C Fruchart; B Staels
Journal:  Inflamm Res       Date:  2000-10       Impact factor: 4.575

6.  Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.

Authors:  T Tanaka; H Kohno; S Yoshitani; S Takashima; A Okumura; A Murakami; M Hosokawa
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

Review 7.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis.

Authors:  Ulf Panzer; André Schneider; Youfei Guan; Rüdiger Reinking; Gunther Zahner; Sigrid Harendza; Gunter Wolf; Friedrich Thaiss; Rolf A K Stahl
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

9.  Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.

Authors:  P Desreumaux; L Dubuquoy; S Nutten; M Peuchmaur; W Englaro; K Schoonjans; B Derijard; B Desvergne; W Wahli; P Chambon; M D Leibowitz; J F Colombel; J Auwerx
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

10.  Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats.

Authors:  H Kohno; S Yoshitani ; S Takashima; A Okumura; M Hosokawa; N Yamaguchi; T Tanaka
Journal:  Jpn J Cancer Res       Date:  2001-04
View more
  3 in total

1.  Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease.

Authors:  Sara Borniquel; Emmelie A Jansson; Marsha P Cole; Bruce A Freeman; Jon O Lundberg
Journal:  Free Radic Biol Med       Date:  2009-11-20       Impact factor: 7.376

2.  PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages.

Authors:  Andreas von Knethen; Mathias Soller; Nico Tzieply; Andreas Weigert; Axel M Johann; Carla Jennewein; Roman Köhl; Bernhard Brüne
Journal:  J Cell Biol       Date:  2007-02-26       Impact factor: 10.539

Review 3.  LRG1: an emerging player in disease pathogenesis.

Authors:  Carlotta Camilli; Alexandra E Hoeh; Giulia De Rossi; Stephen E Moss; John Greenwood
Journal:  J Biomed Sci       Date:  2022-01-21       Impact factor: 12.771
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.